Results 231 to 240 of about 609,876 (337)

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Inflammation and Cardiovascular Risk: A Systematic Review of High-Sensitivity CRP as a Prognostic Indicator. [PDF]

Cureus
Zaidi SUEA, Mohammad A, Ahmad I, Singla S, Singla B, Kumawat S, Abbas S.   +6 more
europepmc   +1 more source

Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons

, 2021
Munuswamy R, De Brandt J, Burtin C, Derave W, Aumann J, Martijn A. Spruit, Michiels L   +6 more
openalex   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Blood Marker-Based Machine Learning Model for Survival Prediction in Patients with Pneumoconiosis: Construction and External Validation. [PDF]

J Inflamm Res
Huang Q, Feng M, Chen Z, Zhang J, Feng Z.   +4 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

Associations of body fat percentage with C-reactive protein levels in Canadian adults with and without osteoarthritis: Findings from the Canadian Longitudinal Study on Aging (CLSA). [PDF]

PLoS One
Marriott KA, Stratford PW, Verschoor CP, Bowdish DME, Mourtzakis M, Chopp-Hurley JN, Wiebenga EG, Maly MR.   +7 more
europepmc   +1 more source

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Risankizumab is a high‐cost biologic treatment for chronic plaque psoriasis, an immune‐mediated inflammatory disease presenting with painful red scaly skin lesions. Inter‐individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (
Charlotte M. Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas‐Hernandez, Jenny Leung, Krystal Rawstron, Chioma Nwaogu, Richard Woolf, Andrew E. Pink, Jonathan Barker, Joseph F. Standing, Catherine H. Smith, Satveer K. Mahil   +16 more
wiley   +1 more source

Editorial: Responding to harm with compassion, accountability, and transparency. [PDF]

Front Health Serv
Benjamin EM, Gallagher TH.
europepmc   +1 more source

Peran Fibrinogen dan hs-CRP sebagai biomarker pada Penyakit Jantung Koroner

, 2015
Otte J Rachman
openalex   +2 more sources